CARDIOLOGY, ONCOLOGY, THERAPEUTICS
A receptor tyrosine kinase inhibitor used to manage renal cell carcinoma, pancreatic neuroendocrine tumours, imatinib-resistant GISTs–gastrointestinal stromal tumours, which may be beneficial in managing other malignancies.
Adverse effects Weakness, nausea, vomiting, diarrhoea, constipation, heartburn, bloating, potentially fatal hepatotoxicity; cardiotoxicity (heart failure, myocardial disorders, and cardiomyopathy) is attributed to pericyte damage due to defects in signalling by platelet-derived growth factor receptor, which may be reversed by thalidomide.
Other names SU11248, Sutent
References Sci Transl Med 2013; 5:187ra69